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Abstract: The biological significance of sp3-rich synthetic scaffolds with natural product-like features yet distinct global frameworks is being 
increasingly recognised in medicinal chemistry and biochemistry. Taking inspiration from the vast array of bioactive, bridged alkaloids, we report 
the synthesis of unique, densely functionalised tricyclic scaffolds based on nitrogen-bridged, octahydrobenzofurans and octahydroindoles. 
These heterocycle-rich frameworks were assembled by a one-pot, two-step bridge-forming reductive amination process, which was shown to 
proceed via caged, heteroadamantane intermediates that thermodynamically drive an exo–endo epimerisation, enabling intramolecular aza-
Michael addition over the concave face of the fused bicyclic precursors. In addition to evaluating the scope of this aza bridge-forming reaction, 
further stereochemical complexity was introduced by subsequent diastereoselective ketone reductions and other manipulations. Finally, 
strategic diversity points (amino, carboxy) were decorated with common medicinal chemistry fragments, providing a set of exemplar derivatives 
with Lipinski compliant physicochemical properties. 
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Introduction 
Humanity has a constant need for the development of new small molecule therapeutics that provide improved target selectivity, 
overcome developing resistance and/or act on new biological targets. In the modern era, the increasing complexity of emerging drug 
targets (e.g., protein-protein interactions[1]) underscores the need for high quality, lead compounds in the drug development process. 
In the crucial lead optimisation stages and beyond, molecules with increased stereochemical complexity, saturation, functionality and 
rigidity have a distinct advantage,[2] such that there is greater potential for highly specific target binding with minimal entropic penalty 
and for improving potency and selectivity through exploration of discrete vectors around a three-dimensional-like surface.[3–5] These 
desirable structural features are often manifested in polycyclic natural products and their derivatives, which have not only found 
application as pharmaceutical drugs[6] but have also informed the design of synthetically tractable, non-natural biological tools and 
medicines with diverse biological activities.[7–9] 
Polycyclic alkaloids in which nitrogen is incorporated into a bridged ring system represent a vast and important subset of biologically 
active natural products,[10,11] many of which are included on the World Health Organisation’s Model List of Essential Medicines.[12] 
Prominent examples include the central nervous system drugs morphine (1, Figure 1) and atropine (2) and the antimalarial agent 
quinine (3).[13a] Non-natural, nitrogen polyheterocycles such as the antiemetic granisetron (4) and the benzomorphan analgesic 
pentazocine (5) are also among FDA-approved medications based on aza-bridged frameworks.[13] 
 
 
Figure 1. Natural and synthetic nitrogen-bridged, polycyclic drugs. 
In our ongoing efforts[14] to develop innovative scaffolds for the European Lead Factory (ELF) drug discovery initiative, [15] we became 
interested in work by Johnson[16] and separately, Coeffard and Greck,[17] describing enantio- and diastereoselective organocatalysed 
annulations of quinols and quinamines (6) with α,β-unsaturated aldehydes (Scheme 1). In a compelling application of the bicyclic 
products 7, Johnson reported one example of a reductive amination to give 8a, in which the existing rings were bridged via an aza-
Michael addition, enabled by an uncommon exo–endo epimerisation at C-3 proven by deuterium incorporation.[16,18] While a small 
number of bridged alkaloids or derivatives incorporating the analogous carbocyclic skeleton of 8 (where X = CH2 or [CH2]2) as a 
substructure have been described,[19] the polyheterocyclic framework of 8 (where X = O, NR) comprising both fused and bridged 
saturated heterocycles has otherwise not been reported. Thus, intrigued by the unique, densely decorated skeleton of 8 as a starting 
point for drug discovery, we present here our preliminary investigations into the synthesis of analogues of 8 (8b–i) and further 
derivatives (16a–z), including an evaluation of the scope and limitations of the bridge-forming reductive amination with respect to the 
amine (RNH2). In addition, we have identified a driving force for the exo–endo epimerisation of the formyl-bearing stereocentre (C-3) 
that occurs during the reductive amination, through the isolation and characterisation of stable, (pre-reduction) caged intermediates 
(9). 
 
Scheme 1. Previous and current work. a) Depicted as the opposite enantiomer to reported. 
 
Results and Discussion 
Given the main objectives of this study were to explore derivatives of 8 with variations in R and Y (structure 16, Scheme 1) and to 
uncover the mechanism of the bridge-forming reductive amination, the substituents at R1 and R2 (structures 7 and 8, Scheme 1) were 
fixed throughout as methyl and phenyl, respectively. Thus, the required bicyclic adducts 7a–c were prepared from cinnamaldehyde 
and the corresponding quinol or N-sulfonylquinamine using the respective organocatalysis conditions described previously (Scheme 
2).[16,17] We demonstrated successful scale-up (up to 6.0 g obtained) with comparable yields and diastereoselectivities to previously 
reported. In all cases, however, the products were prepared as racemates as preferred for first generation screening collections via the 
ELF’s Joint European Compound Library (JECL).[20] 
 
 
Scheme 2. Annulation reactions. a) Conditions: [Si] = TMS, 4-nitrobenzoic acid (20 mol %), toluene, rt, 40 h. b) Diastereomeric ratio determined by 1H NMR and 
refers to the ratio of the major diastereomer (depicted) relative to the sum of others combined. c) Conditions: [Si] = TBS, NaOAc (1 equiv), CHCl3, 55 °C, 96 h (+ 10 
mol % catalyst after 65 h). d) Isolated with an unidentified side product (purity = 81 mol %). 
 
Although up to two other diastereomers accompanied the formation of 7a–c in each case (Scheme 2), we strategically did not 
attempt their separation from the major isomers and the relative configurations of these minor components were not determined. 
Instead, using the diastereomeric mixture of 7 directly in the next step (Scheme 3) was expected to prove more practical and avoid 
potential losses to the overall yield of 8, given the diastereoconvergent nature of the subsequent bridge formation with respect to 7 and 
its C-3 epimer.[21] Accordingly, the bridge-forming reductive amination was investigated using the diastereoenriched bicyclic adducts 
7a–c (Scheme 3). Reaction conditions for the one-pot process were directly adapted from Johnson’s seminal example,[16] although 
reaction times for the initial condensation and subsequent reduction varied depending on the substrate (7a–c) and amine (RNH2) used 
(see the Supporting Information). Products (8) epimeric at C-2 were not observed in the crude reaction mixtures, indicating that any 
minor diastereomers in precursor 7 epimeric at C-2 reacted via other pathways. In fact, the desired tricycle 8 was generally the sole 
product observed after work-up by NMR spectroscopic analysis, which suggested oligomerisation as a competing pathway to account 
for the overall mass balance.[22] This facilitated the straightforward isolation of all bridged products (8) as single diastereomers following 
flash chromatography.  
Our opening experiment to assess the reaction scope was carried out with benzofuran 7a and 4-methoxybenzylamine to give 8b in 
59% yield (Scheme 3).[23] Next, reactions with 4-methoxybenzylamine were successfully extended to sulfonamides 7b and 7c to give 
octahydroindole-containing tricycles 8c and 8d in 72% and 54% yields, respectively. The structure of 8c was confirmed by X-ray 
crystallography. Amines of biological relevance and/or downstream synthetic utility were then evaluated and were found to be well 
tolerated including methylamine, glycine esters and allylamine to give 8f–i in moderate yields (46–62%). The N-unsubstituted cyclic 
amine 8e was also directly accessible from 7a and ammonium acetate using this methodology, however a decrease in yield was 
observed (38%).[24] A notable feature of this method is its practical simplicity: all reactions were performed under air at room temperature 
with standard grade solvents and reagents. This aided the straightforward preparation of selected polycycles 8b and 8e–g on 
synthetically useful scales (5 mmol) which were isolated in 0.5–1.0 g quantities (percentage yields shown in Scheme 3). Amines that 
did not form the desired product 8 when combined with 7a under the standard conditions included N-Boc-ethylenediamine, 
triphenylmethylamine and O-benzylhydroxylamine. In these cases, the reactions proceeded with complete consumption of 7a, but gave 
intractable mixtures containing, at most, traces of the desired products as ascertained by 1H NMR spectroscopic analysis. 
 
Scheme 3. Scope of the bridge-forming reductive amination. a) Reactions performed on 1.0–5.0 mmol scale. See Scheme 2 for precise dr of reactants 7a–c. b) 
Yields are isolated yields as single diastereomers and are uncorrected for any diastereomers in 7a–c epimeric at C-2. c) Diastereomeric ratio of precursor 7a = 
2.1:1.0. d) The X-ray crystal structure of 8c is depicted as the opposite enantiomer to drawn. e) Yield uncorrected for impurity (19 mol %) in precursor 7c. f) Reaction 
performed with NH4OAc (3 equiv) as the ammonia source. g) Reaction performed with the corresponding amine hydrochloride salt (2 equiv) with NEt3 (2 equiv) as 
an additive. 
With a collection of tricyclic scaffolds 8b–i prepared, we proceeded to investigate the mechanism of the reductive amination process. 
To gain further insight into the C-3 exo–endo epimerisation, we attempted to isolate the reaction intermediates from amine condensation 
by omitting the subsequent reduction step. Accordingly, 7a was treated with 4-methoxybenzylamine under the acidic conditions and 
the reaction was quenched after complete consumption of 7a (Scheme 4). Interestingly, analysis of the organic extract by NMR 
spectroscopy revealed complete disappearance of both the aldehyde and enone (alkene) functional groups of 7a, indicating that an 
aza-Michael addition had likely taken place in the absence of the reducing agent. Although several unidentified products were formed, 
the major product 9 was isolated by flash chromatography in the form of separable acetal 9a and hemiacetal 9b (48% combined yield). 
It should be noted that the isolated ratio of 9a/9b (0.8:1.0) was significantly decreased from that originally observed in the crude mixture 
(≥5:1), indicating that partial acetal–hemiacetal exchange occurred during silica gel chromatography.[25] Otherwise, both forms of 9 
were stable and could be fully characterised and stored without any special precautions. This enabled confirmation of the caged 
structure of 9b by X-ray crystallography, which is reminiscent of natural products such as fusidilactone C,[26] tetrodotoxin,[27] 
daphnezomine A[28] and caloundrin B[29] that contain heteroadamantane cores with O–C–O or O–C–N linkages. 
 
Scheme 4. Isolation of key intermediate 9 in the bridge-forming reductive amination. a) Isolated yield after silica gel chromatography as a single diastereomer, 
uncorrected for any diastereomers in 7a epimeric at C-2. b) Ratio 9a/9b before silica gel chromatography ≥5:1. c) Isolated with 12 mol % of a minor product, 
tentatively assigned as the corresponding caged aminal (see the Supporting Information). d) Yield determined by 1H NMR with mesitylene as internal standard. 
 
When the isolated samples of 9a and 9b were separately subjected to the standard reduction conditions with NaBH3CN 
(Scheme 4), clean formation of tricyclic product 8b was observed in both cases (72% and 77% NMR yields, respectively).  
Based on the above findings (Scheme 4), a dynamic mechanism is proposed for the bridge-forming process, whereby aza-Michael 
addition occurs prior to reduction (Scheme 5).[30,31] Initial condensation of aldehyde 7 and the amine (RNH2) would give imine (3-exo)-
10, which could undergo reversible epimerisation to diastereomer (3-endo)-10 under the acidic conditions. Addition of water or methanol 
to (3-endo)-10 would provide hemiaminal (ether) 11, which places the nitrogen in the required orientation to undergo an intramolecular 
aza-Michael addition to the concave face of the enone.[32] Subsequent hemiacetal formation at the ketone of tricycle 12 (via 13) would 
enable intramolecular trapping of the derived iminium ion 14 to produce the observed, stable intermediate 9, which presumably drives 
the overall equilibrium and the initial epimerisation of 10. Upon addition of the hydride source (step 2), the irreversible reduction of 
iminium ions 14 or 15 perturbs the equilibrium and promotes cleavage of the heteroadamantane core of 9 by sequential hemiaminal 
ether fragmentation and acetal collapse, ultimately giving the half-caged product 8. 
 
 
Scheme 5. Proposed mechanism of the bridge-forming reductive amination. 
 
To gain access to fully-saturated core derivatives, the prochiral ketone of selected polycycles 8b, 8e–g and 8i was subjected to 
diastereoselective reduction under substrate dependent conditions (Scheme 6). Treatment of 8b, 8e and 8f with L-selectride resulted 
in exclusive equatorial hydride delivery to give axial alcohols 16a–c in 69–78% yields. Again, this transformation was demonstrated on 
preparative scales, with up to 1.0 g of material isolated (for 16a). The relative stereochemistry of 16b was determined by X-ray 
crystallographic analysis of the dimesylate derivative 16f (Scheme 7), while 16c was independently prepared from 16b by reductive N-
methylation thus confirming the analogous stereochemistry (Scheme 7). The structure of 16a was assigned by analogy. 
In general, the sterically encumbered ketone of scaffold 8 proved relatively slow to reduce, which introduced some chemoselectivity 
issues in the presence of the ester functionalities of 8g and 8i. For example, reduction of the methyl ester group in 8g occurred at a 
competitive rate to ketone reduction using both L-selectride and NaBH4 (in THF or i-PrOH). This necessitated ‘protection’ of the methyl 
ester as the lithium carboxylate salt prior to ketone reduction with L-selectride, allowing isolation of alcohol 16d (50%) over a three-step 
process (Scheme 6). An alternative synthesis of 16d via N-alkylation of 16b with methyl bromoacetate (78%) was also carried out to 
confirm the expected relative stereochemistry (Scheme 7). The tert-butyl ester of 8i was also incompatible with L-selectride but proved 
inert to NaBH4, allowing selective ketone reduction to give a mixture of diastereomers 16e (66%) and (5-epi)-16e (17%) which were 
separated by column chromatography (Scheme 6). Similar to the previous reductions with L-selectride, the major diastereomer 16e 
had the axial configuration at the hydroxy group as confirmed by X-ray crystallography. 
  
Scheme 6. Synthesis of alcohols 16a–e by diastereoselective ketone reduction. Structures of starting materials 8b, 8e–g and 8i are shown in Scheme 3. a) Yields 
are isolated yields as single diastereomers. b) Reaction performed at –40 °C–rt. c) 13% of 8b was recovered. d) 26% of 8f was recovered. e) 14% starting material 
was recovered in the form of a methyl enol ether (see the Supporting Information). f) Isolated dr = 14:1. 
 
 
Scheme 7. Divergent synthesis of 16c, 16d and 16f from amine 16b. 
 
To introduce other useful functionality, representative alcohol 16c was converted into mesylate derivative 16g in high yield (94%, 
Scheme 8), which was subjected to nucleophilic SN2 displacement with sodium azide to give 16h (74%). Subsequent Staudinger 
reduction and treatment with Boc2O gave the protected primary amine 16i in 60% yield over the two steps. 
 
Scheme 8. Synthesis of Boc-protected amine 16i. a) Isolated with a minor alkene impurity (7% w/w) arising from elimination of MsOH. b) Yield uncorrected for 
alkene impurity (7% w/w) in azide 16h. 
 
By design, several of the reduced scaffolds (16) were decorated with modifiable (protected) amino or carboxy groups, thus 
presenting opportunities to create larger compound libraries by further derivatisation. To demonstrate this capability, esters 16d and 
16e and N-Boc-amine 16i were deprotected to give intermediates 16j–l, which, along with amine 16b, were elaborated in divergent 
fashion to an exemplar set of 14 final compounds 16m–z using standard transformations (Scheme 9). Except for 16v, these derivatives 
(16m–z) were prepared using high-throughput techniques (plate format/preparative HPLC purification) and the yields are unoptimised. 
 Scheme 9. Synthesis of derivatives 16j–z. a) Amidation conditions: amine/carboxylic acid, HATU, NEt(i-Pr)2, DMF, rt, 16 h. b) Reductive alkylation conditions: 
aldehyde, (NMe4)BH(OAc)3, AcOH, DMF, rt, 16 h. c) Sulfonylation conditions: sulfonyl chloride, pyridine, DMF, rt, 16 h. d) Yield of crude product after work-up, 
judged to be of ≥90 mol % purity by NMR spectroscopic analysis. Used in the next step without further purification.  
 
Analysis of the 14 exemplar compounds 16m–z using the computational model LLAMA[33] predicts favourable pharmacokinetic 
properties[34] within Lipinski space;[35] specifically: an average molecular weight of 401, AlogP of 2.3, topological polar surface area of 
61.1 Å2 and low rotatable bond count of 3.4 (Table S1). The average “fraction sp3” of the molecules (16m–z), many of which have been 
decorated with (hetero)aromatic groups, is 0.55 (Table S1), which is above the average “fraction sp3” (0.47) of marketed drugs from 
1980–2009.[2a] Further, the overall three-dimensional nature of the tricyclic scaffolds is supported by an average plane-of-best-fit 
(PBF)[36] deviation of 1.1 Å (Table S1), which compares favourably with that of the ChEMBL database[37] of published bioactive 
compounds (average PBF for ChEMBL compounds = 0.6 Å).[3] Taken collectively, these data reveal an encouraging physiochemical 
profile that would appear to make these scaffolds promising candidates for biological screening. 
 
Conclusion 
A total of thirty four derivatives (8b–i and 16a–z) of densely functionalised tricyclic scaffolds based on aminomethyl-bridged, 
octahydrobenzofurans and indoles have been prepared. Construction of the key aza-containing bridge was achieved by a one-pot, two-
step reductive amination process, in which a formyl group on the convex face of the bicyclic precursor was linked to the concave face 
of a distal enone via a stereodynamic amino-condensation process, driven by the formation of stable heteroadamantane intermediates. 
This (reductive) bridge-forming reaction was amenable to a variety of amines with associated biological relevance and/or downstream 
synthetic utility and has provided preparative access to (octahydro)benzofuran and N-sulfonylindole-based tricycles, which were further 
elaborated by diastereoselecive reduction and other standard transformations, including to 14 drug-like examples (16m–z).  
These synthetically tractable scaffolds (16) contain many attractive features for biological applications including a high heterocycle 
and sp3-content and provide numerous points of potential diversity to be explored in further synthetic and biological studies (i.e., X, Y, 
R, R1, R2 of structures 8 and 16 in Scheme 1). Furthermore, the elucidation of the bridge-forming reductive amination pathway opens 
up intriguing opportunities to create even greater structural and stereochemical complexity by the diastereoselective addition of carbon 
nucleophiles to the half-caged iminium ions (14 or 15) in the second step of the bridge-forming process. 
Experimental Section 
General Methods: All reactions were carried out in standard laboratory glassware with magnetic stirring. Thin layer chromatography 
(TLC) was performed on aluminium-backed Silica Gel 60 plates with fluorescent indicator F254. Visualisation was accomplished with 
UV light, a ninhydrin staining solution and/or a phosphomolybdic acid staining solution. Flash chromatography was performed under 
positive air pressure using Silica Gel 60 of 230−400 mesh (40−63 m). Melting points were determined using a Gallenkamp (Griffin) 
Melting Point Apparatus and are uncorrected. Infrared (IR) spectra were obtained on a Bruker ALPHA FTIR Spectrometer with neat 
samples. Proton and carbon magnetic resonance spectra (1H NMR and 13C NMR) were recorded on Bruker 300 MHz, 400 MHz or 500 
MHz spectrometers as specified. Spectra acquired in CDCl3 are reported relative to tetramethylsilane (1H:  = 0.00 ppm) and solvent 
resonance (13C:  = 77.0 ppm). Spectra acquired in CD3OD are reported relative to solvent resonance (1H:  = 3.31 ppm; 13C:  = 49.0 
ppm). High resolution mass spectrometry (HRMS) was performed on a Bruker MicrOTOF II mass spectrometer with electrospray 
ionisation. Cambridge Crystallographic Data Centre (CCDC) deposition numbers are as follows: compound 8c: 1812879, compound 
9b: 1812878, compound 16e: 1812881, compound 16f: 1812880. 
 
Synthesis of 7a–c via Organocatalysed Annulation 
(±)-(2R,3S,3aS,7aS)/(2S,3R,3aR,7aR)-7a-Methyl-5-oxo-2-phenyl-2,3,3a,4,5,7a-hexahydrobenzofuran-3-carbaldehyde (7a): 
Based on a literature procedure,[16] to a mixture of quinol 6a (3.564 g, 28.71 mmol), 4-nitrobenzoic acid (959.6 mg, 5.74 mmol) and the 
racemic organocatalyst (±)-α,α-diphenylprolinol trimethylsilyl ether (1.869 g, 5.74 mmol) in reagent grade toluene (114.8 mL) was added 
neat trans-cinnamaldehyde (5.42 mL, 43.06 mmol) and the mixture was stirred at rt under an air atmosphere for 40 h. The solvent was 
removed under reduced pressure and EtOAc (120 mL) was added. The solution was washed with saturated NaHCO3 (2 × 50 mL) to 
remove the benzoic acid, dried (Na2SO4) and concentrated. Flash chromatography (126 g silica, 22% to 28% EtOAc/light petroleum) 
gave 7a (5.971 g, 81%, dr major/[others combined] = 4.1:1.0) as a yellow gum. The major diastereomer was assigned as the all-exo 
isomer (shown above) based on agreement with literature data.[16] TLC (40% EtOAc/light petroleum): RF’s = 0.53 [minor diastereomer], 
0.43 [major diastereomer], 0.33 [minor diastereomer] (UV or phosphomolybdic acid stain). IR: v = 2974, 2737, 1716, 1675, 1120, 1044, 
700 cm–1. 1H NMR (300 MHz, CDCl3, major diastereomer only): δ  = 9.00 (d, J = 2.1 Hz, 1H), 7.39–7.25 (m, 5H), 6.72 (dd, J = 10.3, 1.9 
Hz, 1H), 6.09 (dd, J = 10.3, 1.1 Hz, 1H), 5.23 (d, J = 9.4 Hz, 1H), 3.14 (dd, J = 9.3, 2.0 Hz, 1H), 3.09–3.05 (m, 1H), 2.72 (dd, J = 17.4, 
5.3 Hz, 1H), 2.56 (ddd, J = 17.4, 2.2, 1.1 Hz, 1H), 1.68 (s, 3H). 13C NMR (75 MHz, CDCl3, major diastereomer only): δ = 198.9, 196.4, 
152.0, 136.9, 129.9, 128.9, 128.5, 126.4, 79.6, 79.2, 60.5, 43.1, 37.3, 23.3. HRMS (ES+): calcd. for C17H20NaO4 [M+MeOH+Na]+ 
311.1254, found 311.1249. The obtained mixture of diastereomers was used in the next step without any complications. 
(±)-(2R,3S,3aS,7aS)/(2S,3R,3aR,7aR)-7a-Methyl-5-oxo-2-phenyl-1-(4-toluenesulfonyl)-2,3,3a,4,5,7a-hexahydro-1H-indole-3-
carbaldehyde (7b): Based on a literature procedure,[17] to a mixture of quinamine 6b (1.387 g, 5.00 mmol), sodium acetate (410.2 mg, 
5.00 mmol) and the racemic organocatalyst (±)-α,α-diphenylprolinol tert-butyldimethylsilyl ether (367.6 mg, 1.00 mmol) in reagent grade 
chloroform (50 mL) was added neat trans-cinnamaldehyde (0.94 mL, 7.50 mmol) and the mixture was stirred at 55 °C under an initial 
air atmosphere for 65 h (sealed flask with argon balloon equaliser). A second portion of the solid TBS organocatalyst (183.8 mg, 0.50 
mmol) was added and stirring continued at 55 °C for a further 31 h (total reaction time = 96 h). The solvent was removed under reduced 
pressure and the residue subjected to flash chromatography (36 g silica, 30% EtOAc/light petroleum) giving 7b (1.369 g, 67%, dr 
major/[others combined] = 4.5:1.0) as a light orange solid. The major diastereomer was assigned as the all-exo isomer (shown above) 
based on agreement with literature data.[17] TLC (40% EtOAc/light petroleum): RF’s = 0.52 [major diastereomer], 0.38 [minor 
diastereomer], 0.32 [minor diastereomer] (UV). IR: v = 1676, 1331, 1148, 1053, 676, 585, 544 cm–1. 1H NMR (300 MHz, CDCl3, major 
diastereomer only): δ = 9.00 (d, J = 1.3 Hz, 1H), 7.61 (dd, J = 10.5, 2.2 Hz, 1H), 7.22–7.03 (m, 5H), 6.95–6.87 (m, 4H), 5.98 (dd, J = 
10.5, 1.1 Hz, 1H), 5.48 (d, J = 9.7 Hz, 1H), 3.33 (ddd, J = 12.4, 9.9, 1.3 Hz, 1H), 3.11 (ddt, J = 12.4, 4.8, 2.2 Hz, 1H), 2.73 (dd, J = 17.8, 
5.3 Hz, 1H), 2.57 (ddd, J = 17.8, 2.3, 1.2 Hz, 1H), 2.27 (s, 3H), 2.01 (s, 3H). 13C NMR (75 MHz, CDCl3, major diastereomer only): δ = 
197.5, 195.1, 151.6, 143.0, 138.1, 136.2, 128.8, 128.6, 128.2, 127.6, 127.1, 127.0, 66.4, 63.3, 55.1, 44.0, 36.1, 24.1, 21.3. HRMS 
(ES+): calcd. for C24H27NNaO5S [M+MeOH+Na]+ 464.1503, found 464.1510. The obtained mixture of diastereomers was used in the 
next step without any complications. 
(±)-(2R,3S,3aS,7aS)/(2S,3R,3aR,7aR)-7a-Methyl-5-oxo-2-phenyl-1-methanesulfonyl-2,3,3a,4,5,7a-hexahydro-1H-indole-3-
carbaldehyde (7c): Based on a literature procedure for the tosyl analogue,[17] to a mixture of quinamine 6c (1.006 g, 5.00 mmol), 
sodium acetate (410.2 mg, 5.00 mmol) and the racemic organocatalyst (±)-α,α-diphenylprolinol tert-butyldimethylsilyl ether (367.6 mg, 
1.00 mmol) in reagent grade chloroform (50 mL) was added neat trans-cinnamaldehyde (0.94 mL, 7.50 mmol) and the mixture was 
stirred at 55 °C under an initial air atmosphere for 65 h (sealed flask with argon balloon equaliser). A second portion of the solid TBS 
organocatalyst (183.8 mg, 0.50 mmol) was added and stirring continued at 55 °C for a further 31 h (total reaction time = 96 h). The 
solvent was removed under reduced pressure and the residue subjected to flash chromatography (20 g silica, 33% to 40% EtOAc/light 
petroleum) giving a pale orange solid (1.346 g) which consisted of 7c with a minor diastereomer (dr major/minor = 5.9:1.0) and an 
unidentified side product (ratio of combined diastereomers/side product = 4.3:1.0). The mass of the mixed sample obtained (1.346 g) 
was equivalent to 81% yield of 7c with 81 mol % purity (yield and purity for combined diastereomers). The major diastereomer was 
assigned as the all-exo isomer (shown above) by analogy with the known N-tosyl analogue.[17] TLC (40% EtOAc/light petroleum): RF’s 
= 0.39 [unknown side product], 0.32 [major diastereomer], 0.22 [minor diastereomer] (UV or weak with phosphomolybdic acid stain). 
IR: v = 1679, 1326, 1145, 962, 758, 702, 520 cm–1. 1H NMR (300 MHz, CDCl3, major diastereomer only): δ = 9.09 (d, J = 0.9 Hz, 1H), 
7.52–7.19 (m, 6H), 5.96 (dd, J = 10.5, 1.1 Hz, 1H), 5.47 (d, J = 9.6 Hz, 1H), 3.39 (ddd, J = 12.4, 9.6, 1.0 Hz, 1H), 3.28 (ddt, J = 12.4, 
4.7, 2.2 Hz, 1H), 2.83–2.74 (m, 1H), 2.70–2.61 (m, 1H), 2.49 (s, 3H), 1.97 (s, 3H). 13C NMR (75 MHz, CDCl3, major diastereomer only): 
δ = 197.2, 195.0, 151.6, 137.0, 129.4, 129.2, 127.8, 127.1, 65.6, 63.1, 55.0, 44.8, 44.6, 36.2, 23.6. HRMS (ES+): calcd. for 
C18H23NNaO5S [M+MeOH+Na]+ 388.1190, found 388.1186. The obtained mixture was used in the next step without any complications. 
Synthesis of 8b–i via Bridge-Forming Reductive Amination 
(±)-(2R,3S,3aS,7S,7aR)/(2S,3R,3aR,7R,7aS)-8-(4-Methoxybenzyl)-7a-methyl-2-phenylhexahydro-7,3-
(epiminomethano)benzofuran-5(4H)-one (8b): To a mixture of annulation product 7a (1.185 g, 4.62 mmol, dr major/[others combined] 
= 2.1:1.0) and 4-methoxybenzylamine (1.21 mL, 9.25 mmol) in reagent grade MeOH (41.6 mL) was added AcOH (4.6 mL) and the 
solution was stirred at rt under an air atmosphere for 4 h. Solid NaBH3CN (581.1 mg, 9.25 mmol) was added at once (caution: gas 
evolution) and stirring was continued for 30 min at rt under air. A second portion of NaBH3CN (209.5 mg, 4.62 mmol) was added and 
stirring continued for a further 2 h. The mixture was poured into NaOH (2 M in water, 65 mL) and most of the MeOH was then removed 
under reduced pressure. Brine (20 mL) and water (10 mL) were added and the product was extracted with EtOAc (130 mL + 30 mL). 
The combined extracts were dried (Na2SO4) and concentrated. 1H NMR spectroscopic analysis of the residue showed the desired 
product and caged acetal 9a (from incomplete reduction) in an approximate 11:1 molar ratio, respectively. Flash chromatography (54 
g silica, 18% to 25% EtOAc/light petroleum) gave 8b (1.035 g, 59% [uncorrected for diastereomeric impurities in starting material], 
single diastereomer) as a colourless foam. TLC (40% EtOAc/light petroleum): RF = 0.44 (UV or phosphomolybdic acid stain). IR: v = 
2899, 2799, 1707, 1510, 1241, 1001, 727, 700 cm–1. 1H NMR (300 MHz, CDCl3): δ = 7.36–7.29 (m, 6H), 7.27–7.19 (m, 1H), 6.89–6.83 
(m, 2H), 5.22 (s, 1H), 3.79 (s, 3H), 3.69 (ABq, ΔδAB = 0.10, J = 13.3 Hz, 2H), 3.21–3.15 (m, 1H), 2.87 (dd, J = 17.4, 2.8 Hz, 1H), 2.76 
(dd, J = 12.6, 3.3 Hz, 1H), 2.59–2.49 (m, 3H), 2.36–2.26 (m, 3H), 1.68 (s, 3H). 13C NMR (75 MHz, CDCl3): δ = 209.6, 158.7, 144.0, 
130.5, 129.6, 128.0, 126.7, 125.0, 113.7, 82.7, 79.3, 63.0, 56.7, 55.2, 48.7, 47.9, 40.2, 39.0, 38.6, 22.1. HRMS (ES+): calcd. for 
C24H28NO3 [M+H]+ 378.2064, found 378.2065. 
(±)-(2R,3S,3aS,7S,7aR)/(2S,3R,3aR,7R,7aS)-8-(4-Methoxybenzyl)-7a-methyl-2-phenyl-1-(4-toluenesulfonyl)octahydro-5H-7,3-
(epiminomethano)indol-5-one (8c): To a mixture of annulation product 7b (409.5 mg, 1.00 mmol, dr major/[others combined] = 
4.5:1.0) and 4-methoxybenzylamine (0.26 mL, 2.00 mmol) in reagent grade MeOH (9.0 mL) was added AcOH (1.0 mL) and the 
suspension was stirred at rt under an air atmosphere for 6 h (after 5.5 h the mixture became fully homogenous). Solid NaBH3CN (125.7 
mg, 2.00 mmol) was added at once (caution: gas evolution) and stirring was continued for 30 min at rt under air. A second portion of 
NaBH3CN (62.8 mg, 1.00 mmol) was added and stirring continued for a further 20 min. The mixture was poured into NaOH (2 M in 
water, 15 mL) and most of the MeOH was then removed under reduced pressure. Brine (20 mL) was added and the product was 
extracted with EtOAc (50 mL + 25 mL). The combined extracts were dried (Na2SO4) and concentrated. Flash chromatography (11.7 g 
silica, 30% EtOAc/light petroleum) gave 8c (383.6 mg, 72% [uncorrected for diastereomeric impurities in starting material], single 
diastereomer) as a pale yellow solid; m.p. 98‒100 °C. TLC (40% EtOAc/light petroleum): RF = 0.51 (UV). IR: v = 2937, 1710, 1511, 
1243, 1152, 1088, 672, 542 cm–1. 1H NMR (300 MHz, CDCl3): δ = 7.51 (d, J = 8.1 Hz, 2H), 7.37–7.33 (m, 2H), 7.17–6.98 (m, 5H), 6.96–
6.87 (m, 4H), 5.20 (s, 1H), 3.98–3.90 (m, 1H), 3.81 (s, 3H), 3.77 (d, J = 12.8 Hz, 1H), 3.61 (d, J = 12.8 Hz, 1H), 2.86 (dt, J = 17.8, 2.5 
Hz, 1H), 2.78 (dd, J = 12.9, 3.4 Hz, 1H), 2.65–2.52 (m, 2H), 2.47–2.33 (m, 3H), 2.33 (s, 3H), 1.97–1.91 (m, 1H), 1.89 (s, 3H). 13C NMR 
(75 MHz, CDCl3, one ArC signal ‘missing’ due to overlap): δ = 208.9, 158.7, 142.2, 141.1, 140.3, 130.2, 128.7, 127.8, 126.93, 126.91, 
126.6, 113.6, 68.5, 66.7, 62.2, 57.5, 55.1, 47.6, 46.8, 41.9, 39.1, 37.9, 21.3, 21.2. HRMS (ES+): calcd. for C31H35N2O4S [M+H]+ 531.2312, 
found 531.2321. 
(±)-(2R,3S,3aS,7S,7aR)/(2S,3R,3aR,7R,7aS)-1-Methanesulfonyl-8-(4-Methoxybenzyl)-7a-methyl-2-phenyloctahydro-5H-7,3-
(epiminomethano)indol-5-one (8d): To a mixture of annulation product 7c (333.4 mg, 1.00 mmol, dr major/minor = 5.9:1.0, 81 mol % 
purity) and 4-methoxybenzylamine (274.4 mg, 2.00 mmol) in reagent grade MeOH (9.0 mL) was added AcOH (1.0 mL) and the solution 
was stirred at rt under an air atmosphere for 4 h. Solid NaBH3CN (125.7 mg, 2.00 mmol) was added at once (caution: gas evolution) 
and stirring was continued for 30 min at rt under air. NaOH (2 M in water, 12 mL) was added and most of the MeOH was then removed 
under reduced pressure. Water (20 mL) was added and the product was extracted with EtOAc (30 mL + 20 mL). The combined extracts 
were dried (Na2SO4) and concentrated. Flash chromatography (14.8 g silica, 30% EtOAc/light petroleum) gave 8d (244.9 mg, 54% 
[uncorrected for impurities in starting material], single diastereomer) as a colourless solid; m.p. 183‒186 °C. TLC (50% EtOAc/light 
petroleum): RF = 0.39 (UV or phosphomolybdic acid stain). IR: v = 2909, 2798, 1698, 1511, 1323, 1247, 1144, 1019, 766, 705, 520 cm–
1. 1H NMR (300 MHz, CDCl3): δ = 7.43 (d, J = 8.6 Hz, 2H), 7.38–7.25 (m, 5H), 6.89 (d, J = 8.6 Hz, 2H), 5.07 (s, 1H), 3.82–3.76 (m, 4H), 
3.71 (d, J = 12.8 Hz, 1H), 3.57 (d, J = 12.8 Hz, 1H), 2.90–2.80 (m, 4H), 2.75 (dd, J = 12.9, 3.5 Hz, 1H), 2.72–2.59 (m, 2H), 2.46 (dd, J 
= 16.8, 2.4 Hz, 1H), 2.42–2.33 (m, 2H), 2.00–1.95 (m, 1H), 1.92 (s, 3H). 13C NMR (75 MHz, CDCl3): δ = 208.8, 158.8, 141.9, 130.2, 
130.0, 128.5, 127.5, 126.2, 113.6, 68.2, 66.2, 62.0, 57.5, 55.1, 47.6, 46.6, 45.1, 42.1, 39.1, 37.8, 21.0. HRMS (ES+): calcd. for 
C25H31N2O4S [M+H]+ 455.1999, found 455.2006. 
(±)-(2R,3S,3aS,7S,7aR)/(2S,3R,3aR,7R,7aS)-7a-Methyl-2-phenylhexahydro-7,3-(epiminomethano)benzofuran-5(4H)-one (8e): 
To a mixture of annulation product 7a (1.282 g, 5.00 mmol, dr major/[others combined] = 4.1:1.0) and ammonium acetate (1.156 g, 
15.00 mmol) in reagent grade MeOH (45.0 mL) was added AcOH (5.0 mL) and the solution was stirred at rt under an air atmosphere 
for 18.5 h. Solid NaBH3CN (628.4 mg, 10.00 mmol) was added at once (caution: gas evolution) and stirring was continued for 30 min 
at rt under air. A second portion of NaBH3CN (314.2 mg, 5.00 mmol) was added and stirring continued for a further 3.5 h. After cooling 
in an ice bath, NaOH (2 M in water, 68 mL) was added. Most of the MeOH was then removed under reduced pressure. Brine (40 mL) 
was added and the product was extracted with EtOAc (100 mL + 50 mL). The combined extracts were dried (Na2SO4) and concentrated. 
Flash chromatography (54 g silica, MeOH/[35% aqueous NH3]/EtOAc = 4:1:95) gave 8e (486.7 mg, 38% [uncorrected for diastereomeric 
impurities in starting material], single diastereomer) as an off-white solid; m.p. 46‒48 °C. TLC (MeOH/[35% aqueous NH3]/EtOAc = 
5:1:94): RF = 0.13 (UV or ninhydrin stain). IR: v = 2930, 1704, 1083, 1022, 969, 732, 700 cm–1. 1H NMR (300 MHz, CDCl3): δ = 7.39–
7.31 (m, 4H), 7.29–7.23 (m, 1H), 5.17 (s, 1H), 3.06 (dt, J = 5.5, 2.7 Hz, 1H), 2.98 (dd, J = 14.8, 1.6 Hz, 1H), 2.88 (ddd, J = 14.7, 3.0, 
1.3 Hz, 1H), 2.65–2.55 (m, 4H), 2.43–2.36 (m, 1H), 2.36–2.22 (m, 2H), 1.64 (s, 3H). 13C NMR (75 MHz, CDCl3): δ = 208.9, 143.4, 
128.2, 127.0, 124.9, 83.0, 79.7, 59.2, 49.8, 45.4, 42.9, 40.2, 38.5, 21.9. HRMS (ES+): calcd. for C16H20NO2 [M+H]+ 258.1489, found 
258.1488. 
(±)-(2R,3S,3aS,7S,7aR)/(2S,3R,3aR,7R,7aS)-7a-Methyl-8-Methyl-2-phenylhexahydro-7,3-(epiminomethano)benzofuran-5(4H)-
one (8f): To a solution of annulation product 7a (1.282 g, 5.00 mmol, dr major/[others combined] = 4.1:1.0) in reagent grade MeOH 
(40.0 mL) was added a commercial solution of MeNH2 (2.0 M in MeOH, 5.00 mL, 10.00 mmol), followed by AcOH (5.0 mL) and the 
mixture was stirred at rt under an air atmosphere for 17 h. Solid NaBH3CN (628.4 mg, 10.00 mmol) was added at once (caution: gas 
evolution) and stirring was continued for 1 h at rt under air. A second portion of NaBH3CN (628.4 mg, 10.00 mmol) was added and 
stirring continued for a further 3 h. After cooling in an ice bath, NaOH (2 M in water, 70 mL) was added. Most of the MeOH was then 
removed under reduced pressure. Brine (40 mL) was added and the product was extracted with EtOAc (100 mL + 50 mL). The combined 
extracts were dried (Na2SO4) and concentrated. Flash chromatography (41 g silica, EtOAc/NEt3/light petroleum = 65:1:34) gave 8f 
(776.6 mg, 57% [uncorrected for diastereomeric impurities in starting material], single diastereomer) as a pale yellow foam. TLC 
(EtOAc/NEt3/light petroleum = 80:1:19): RF = 0.38 (UV or weak with phosphomolybdic acid stain). IR: v = 2888, 2795, 1703, 1120, 
1053, 1002, 725, 700 cm–1. 1H NMR (300 MHz, CDCl3): δ = 7.37–7.30 (m, 4H), 7.27–7.20 (m, 1H), 5.18 (s, 1H), 3.12–3.06 (m, 1H), 
2.93–2.78 (m, 2H), 2.61–2.52 (m, 3H), 2.47 (s, 3H), 2.37–2.25 (m, 3H), 1.70 (s, 3H). 13C NMR (75 MHz, CDCl3): δ = 209.4, 143.9, 
128.1, 126.8, 125.0, 82.8, 79.3, 64.6, 50.8, 48.5, 41.1, 39.6, 38.6, 38.1, 22.1. HRMS (ES+): calcd. for C17H22NO2 [M+H]+ 272.1645, 
found 272.1644. 
(±)-(2R,3S,3aS,7S,7aR)/(2S,3R,3aR,7R,7aS)-8-Carbomethoxymethyl-7a-methyl-2-phenylhexahydro-7,3-
(epiminomethano)benzofuran-5(4H)-one (8g): To a mixture of annulation product 7a (1.282 g, 5.00 mmol, dr major/[others combined] 
= 4.1:1.0), glycine methyl ester hydrochloride (1.256 g, 10.00 mmol) and NEt3 (1.012 g, 10.00 mmol) in reagent grade MeOH (45.0 mL) 
was added AcOH (5.0 mL) and the solution was stirred at rt under an air atmosphere for 21.5 h. Solid NaBH3CN (628.4 mg, 10.00 
mmol) was added at once (caution: gas evolution) and stirring was continued for 30 min at rt under air. A second portion of NaBH3CN 
(314.2 mg, 5.00 mmol) was added and stirring continued for a further 2.5 h. After cooling in an ice bath, NaOH (2 M in water, 35 mL) 
was added to raise the pH to 9 (care must be taken for this substrate to prevent saponification of the ester by ensuring the pH does not 
rise above 9), followed by brine (80 mL) and the product was extracted with EtOAc (150 mL + 100 mL). The combined extracts were 
dried (Na2SO4) and concentrated, then placed under high vacuum for 1 h to remove residual water carried through into the organic 
extracts due to the presence of MeOH. Flash chromatography (40.3 g silica, 35% to 38% EtOAc/light petroleum) gave 8g (909.2 mg, 
55% [uncorrected for diastereomeric impurities in starting material], single diastereomer) as a pale yellow foam. TLC (60% EtOAc/light 
petroleum): RF = 0.45 (UV or phosphomolybdic acid stain). IR: v = 2902, 1705, 1195, 1140, 1000, 736, 700 cm–1. 1H NMR (300 MHz, 
CDCl3): δ = 7.39–7.30 (m, 4H), 7.28–7.20 (m, 1H), 5.34 (s, 1H), 3.73 (s, 3H), 3.43 (s, 2H), 3.20–3.16 (m, 1H), 3.10–3.02 (m, 1H), 2.75–
2.66 (m, 2H), 2.60–2.54 (m, 2H), 2.40 (dd, J = 17.2, 3.7 Hz, 1H), 2.36–2.31 (m, 2H), 1.69 (s, 3H). 13C NMR (75 MHz, CDCl3): δ = 208.9, 
171.1, 143.8, 128.0, 126.8, 125.0, 82.6, 79.1, 64.4, 55.2, 51.7, 48.4, 48.3, 40.1, 39.7, 38.5, 22.0. HRMS (ES+): calcd. for C19H24NO4 
[M+H]+ 330.1700, found 330.1700. 
(±)-(2R,3S,3aS,7S,7aR)/(2S,3R,3aR,7R,7aS)-8-Allyl-7a-methyl-2-phenylhexahydro-7,3-(epiminomethano)benzofuran-5(4H)-one 
(8h): To a mixture of annulation product 7a (512.6 mg, 2.00 mmol, dr major/[others combined] = 4.1:1.0) and allylamine (0.30 mL, 4.00 
mmol) in reagent grade MeOH (18.0 mL) was added AcOH (2.0 mL) and the solution was stirred at rt under an air atmosphere for 22 
h. Solid NaBH3CN (251.4 mg, 4.00 mmol) was added at once (caution: gas evolution) and stirring was continued for 1 h at rt under air. 
A second portion of NaBH3CN (251.4 mg, 4.00 mmol) was added and stirring continued for a further 6.5 h. After cooling in an ice bath, 
NaOH (2 M in water, 32 mL) was added. Most of the MeOH was then removed under reduced pressure. Brine (20 mL) was added and 
the product was extracted with EtOAc (50 mL + 25 mL). The combined extracts were dried (Na2SO4) and concentrated. Flash 
chromatography (23.2 g silica, 20% EtOAc/light petroleum) gave 8h (276.2 mg, 46% [uncorrected for diastereomeric impurities in 
starting material], single diastereomer) as a pale yellow gum. TLC (50% EtOAc/light petroleum): RF = 0.63 (UV or phosphomolybdic 
acid stain). IR: v = 2902, 2800, 1706, 1121, 1000, 915, 729, 700 cm–1. 1H NMR (300 MHz, CDCl3): δ = 7.37–7.29 (m, 4H), 7.27–7.19 
(m, 1H), 5.97–5.82 (m, 1H), 5.31–5.11 (m, 3H), 3.32–3.13 (m, 3H), 2.90 (dd, J = 12.6, 3.5 Hz, 1H), 2.80 (dd, J = 17.3, 2.7 Hz, 1H), 2.55 
(d, J = 3.8 Hz, 2H), 2.46 (d, J = 12.6 Hz, 1H), 2.37–2.25 (m, 3H), 1.69 (s, 3H). 13C NMR (75 MHz, CDCl3): δ = 209.5, 143.9, 135.8, 
128.0, 126.7, 125.0, 117.4, 82.7, 79.3, 63.2, 56.5, 48.5, 48.2, 40.1, 38.7, 38.6, 22.1. HRMS (ES+): calcd. for C19H24NO2 [M+H]+ 
298.1802, found 298.1805. 
(±)-(2R,3S,3aS,7S,7aR)/(2S,3R,3aR,7R,7aS)-8-Carbotert-butoxymethyl-1-methanesulfonyl-7a-methyl-2-phenyloctahydro-5H-
7,3-(epiminomethano)indol-5-one (8i): To a mixture of annulation product 7c (333.4 mg, 1.00 mmol, dr major/minor = 5.9:1.0, 81 mol 
% purity), glycine tert-butyl ester hydrochloride (335.3 mg, 2.00 mmol) and NEt3 (202.4 mg, 2.00 mmol) in reagent grade MeOH (9.0 
mL) was added AcOH (1.0 mL) and the mixture was stirred at rt under an air atmosphere for 21 h. Solid NaBH3CN (125.7 mg, 2.00 
mmol) was added at once (caution: gas evolution) and stirring was continued for 30 min at rt under air. A second portion of NaBH3CN 
(62.8 mg, 1.00 mmol) was added and stirring continued for a further 3.5 h. After cooling in an ice bath, NaOH (2 M in water, 10 mL) 
was added. Most of the MeOH was then removed under reduced pressure. Brine (20 mL) was added and the product was extracted 
with EtOAc (50 mL + 25 mL). The combined extracts were dried (Na2SO4) and concentrated. Flash chromatography (13.2 g silica, 27% 
to 30% EtOAc/light petroleum) gave 8i (279.3 mg, 62% [uncorrected for impurities in starting material], single diastereomer) as a 
colourless solid; m.p. 177‒180 °C. TLC (50% EtOAc/light petroleum): RF = 0.46 (UV or phosphomolybdic acid stain). IR: v = 2979, 
1748, 1715, 1322, 1131, 1025, 754, 698, 512 cm–1. 1H NMR (300 MHz, CDCl3): δ = 7.41–7.31 (m, 4H), 7.29–7.21 (m, 1H), 5.00 (s, 
1H), 3.55–3.50 (m, 1H), 3.32–3.12 (m, 3H), 3.00 (s, 3H), 2.74–2.55 (m, 4H), 2.49–2.38 (m, 2H), 2.14–2.06 (m, 1H), 1.92 (s, 3H), 1.49 
(s, 9H). 13C NMR (75 MHz, CDCl3): δ = 207.9, 169.2, 142.3, 128.3, 127.2, 126.1, 81.5, 68.1, 65.5, 62.2, 56.3, 48.2, 47.0, 41.4, 40.7, 
38.9, 38.8, 28.0, 22.4. HRMS (ES+): calcd. for C23H33N2O5S [M+H]+ 449.2105, found 449.2107. 
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